Abstract The shifting legal landscape of drug regulation in the United States has been marked by a growing divergence between state and federal approaches to cannabis and psychedelics. In recent years, numerous states have passed laws legalizing or decriminalizing marijuana and exploring the therapeutic potential of psychedelics, such as psilocybin and MDMA. At the same time, these trends are juxtaposed against rising opposition and legislative rollback, particularly in states like Oregon, where decriminalization efforts have been reversed. This article provides a comprehensive review of current drug policy developments, focusing on cannabis and psychedelics at the state level, the evolving federal stance under the Biden administration, and the potential impact of a second Trump term. It also explores the challenges and successes of state initiatives, the FDA’s evolving role in regulating substances like MDMA and esketamine, and the broader implications for public health and criminal justice. As the country navigates the complexities of drug rescheduling and reform, future federal policies under new leadership could further reshape the landscape of drug legalization and therapy in the United States.
Laura I Appleman (Thu,) studied this question.